首页> 美国卫生研究院文献>Journal of Hematology Oncology >Treatment outcome of thalidomide based regimens in newly diagnosed and relapsed/refractory non-transplant multiple myeloma patients: a single center experience from Thailand
【2h】

Treatment outcome of thalidomide based regimens in newly diagnosed and relapsed/refractory non-transplant multiple myeloma patients: a single center experience from Thailand

机译:沙利度胺为基础的方案在新诊断和复发/难治性非移植性多发性骨髓瘤患者中的治疗结果:来自泰国的单中心经验

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundThalidomide based regimen is an effective and well tolerated therapy in multiple myeloma (MM) patients, however, there were a small number of studies written about the results of thalidomide therapy in non-transplant MM patients. We therefore conducted a retrospective study of 42 consecutive patients with newly diagnosed and relapsed/refractory MM treated with thalidomide- based induction regimens followed by thalidomide maintenance therapy.
机译:背景基于沙利度胺的方案在多发性骨髓瘤(MM)患者中是一种有效且耐受性良好的疗法,但是,针对非移植性MM患者的沙利度胺治疗的结果,已有少量研究报道。因此,我们进行了一项回顾性研究,对连续接受42例新诊断和复发/难治性MM的患者进行了基于沙利度胺的诱导方案治疗,然后进行沙利度胺维持治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号